Drug Patent Expirations in October 2010

Drug Patent Expirations in October 2010

*Drugs may be covered by multiple patents

Tradename Applicant Generic Name Patent Number Patent Expiration
ORGARAN Organon Usa Inc danaparoid sodium 5,164,377 Oct 3, 2010
MIRAPEX ER Boehringer Ingelheim pramipexole dihydrochloride 4,886,812 Oct 8, 2010
MIRAPEX Boehringer Ingelheim pramipexole dihydrochloride 4,886,812 Oct 8, 2010
CLIMARA PRO Bayer Hlthcare estradiol; levonorgestrel 5,770,219 Oct 12, 2010
CLIMARA PRO Bayer Hlthcare estradiol; levonorgestrel 5,252,334 Oct 12, 2010
MENTAX Mylan butenafine hydrochloride 5,021,458 Oct 18, 2010
NUVIGIL Cephalon armodafinil 4,927,855*PED Oct 22, 2010
CETROTIDE Emd Serono cetrorelix 5,198,533 Oct 24, 2010
TRITEC Glaxosmithkline ranitidine bismuth citrate 5,256,684 Oct 26, 2010
INVEGA SUSTENNA Johnson And Johnson paliperidone palmitate 5,254,556 Oct 27, 2010
COMTAN Orion entacapone 5,135,950 Oct 31, 2010
STALEVO 125 Orion carbidopa; entacapone; levodopa 5,135,950 Oct 31, 2010
STALEVO 200 Orion carbidopa; entacapone; levodopa 5,135,950 Oct 31, 2010
STALEVO 75 Orion carbidopa; entacapone; levodopa 5,135,950 Oct 31, 2010
STALEVO 100 Orion carbidopa; entacapone; levodopa 5,135,950 Oct 31, 2010
STALEVO 150 Orion carbidopa; entacapone; levodopa 5,135,950 Oct 31, 2010
STALEVO 50 Orion carbidopa; entacapone; levodopa 5,135,950 Oct 31, 2010

This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin. Courtesy of DrugPatentWatch.com


   No Comments yet


  1. patent litigation
      Nov 1, 2010

    Yes, the “patent cliff” is fast upon us. What with so many biotech and similar companies now starting to face the dreaded moment, now is the time to start diversifying and shoring up their assets, if they haven’t done so already.
    http://www.generalpatent.com/media/videos/patent-suits

Leave a Reply